India's Dr Reddy's to manufacture Biosignal's furanones
Thursday, 20 January, 2005
Sydney-based Biosignal (ASX:BOS) has engaged Custom Pharmaceutical Serivces, a business unit of Indian generics-manufacturing specialist Dr Reddy's Laboratories, to develop a large-scale manufacturing procedure for Biosignal's antibacterial furanone compounds.
Dr Reddy's will then synthesise furanones for use in product development and registration Biosignal's anti-bacterial contact lenses and antifouling paints.
Custom Pharmaceutical Serivces produces cGMP compliant products in ISO certified facilities. Hyderabad-based Dr Reddy's is listed on the NYSE, and is best known for its aggressive pursuit of the generics market, launching numerous patent challenges against big pharma drugs. Its marketing rights for a generic version of Eli Lilly's Prozac ended two years ago. Dr Reddy's is also conducting research into new drugs.
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
